<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833387</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-092</org_study_id>
    <nct_id>NCT04833387</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer</brief_title>
  <official_title>PD-1 Antibody as a Sequential Therapy Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer: an Open, Multi-center, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with&#xD;
      PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal&#xD;
      cancer staged as locally advanced (cT3-T4N+/-M0 for rectal cancer). This treatment will be&#xD;
      given during the window period until surgical resection of the tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>PD-1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>1 year</time_frame>
    <description>Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response (CCR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lynch Syndrome</condition>
  <arm_group>
    <arm_group_label>PD-1 antibody + capecitabine + radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)</description>
    <arm_group_label>PD-1 antibody + capecitabine + radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who personally provided written consent for participation in the study&#xD;
&#xD;
          -  Treatment-naive patients with rectal cancer, in whom the inferior margin of the tumor&#xD;
             was at a distance of 12 cm or less from the AV before CRT&#xD;
&#xD;
          -  Primary rectal cancer histopathologically confirmed to be adenocarcinoma&#xD;
&#xD;
          -  Clinical stage of T3,and T4 ,N any,M0,before CRT&#xD;
&#xD;
          -  Macroscopic radical resection could be feasible, based on diagnostic imaging before&#xD;
             CRT&#xD;
&#xD;
          -  Patients with the ECOG performance status of 0 or 1 at the time of enrollment&#xD;
&#xD;
          -  Patients without distant metastasis on the imaging test before CRT&#xD;
&#xD;
          -  Preoperative biopsy of tumor immunohistochemistry TPS&gt;1% or CPS&gt;1&#xD;
&#xD;
          -  Life expectancy of greater than 2 years&#xD;
&#xD;
          -  No signs of intestinal obstruction; or the obstruction has been relieved after the&#xD;
             proximal colostomy operation&#xD;
&#xD;
          -  Hematology: WBC&gt;4000/mm3; PLT&gt;100000/mm3; Hb&gt;10g/dL&#xD;
&#xD;
          -  Liver function: SGOT and SGPT are less than 1.5 times the normal value; bilirubin is&#xD;
             less than 1.5mg/dL&#xD;
&#xD;
          -  Renal function: creatinine &lt;1.8mg/dL Others: non-pregnant or breast-feeding women; no&#xD;
             other malignant diseases (except for non-melanoma or cervical carcinoma in situ)&#xD;
             within 5 years or during the same period; no mental illness that causes the inability&#xD;
             to obtain informed consent; no other serious diseases that can shorten the survival&#xD;
             time disease.&#xD;
&#xD;
          -  Have not received rectal surgery in the past;&#xD;
&#xD;
          -  Have not received chemotherapy or radiotherapy in the past;&#xD;
&#xD;
          -  Have not received biological treatment in the past;&#xD;
&#xD;
          -  Past endocrine therapy: unlimited.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rectal cancer with unstable microsatellite (MSI or dMMR);&#xD;
&#xD;
          -  Preoperative biopsy of tumor immunohistochemistry TPS≤1% or CPS≤1&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or chronic hepatitis B or C (high&#xD;
             copy viral DNA);&#xD;
&#xD;
          -  Autoimmune diseases;&#xD;
&#xD;
          -  Other active clinical serious infections (&gt;NCI-CTC version 3.0);&#xD;
&#xD;
          -  Patients in clinical phase I;&#xD;
&#xD;
          -  There is evidence that there is distant metastasis before surgery;&#xD;
&#xD;
          -  Cachexia, decompensation of organ function;&#xD;
&#xD;
          -  Have a history of pelvic or abdominal radiotherapy;&#xD;
&#xD;
          -  Multiple primary cancers;&#xD;
&#xD;
          -  Patients who need treatment for seizures (such as steroids or anti-epileptic&#xD;
             treatment);&#xD;
&#xD;
          -  Have a known additional malignant tumors within 5 years. Exceptions include basal cell&#xD;
             carcinoma of the skin that has undergone potentially curative therapy or in situ&#xD;
             cervical cancer;&#xD;
&#xD;
          -  Chronic inflammatory bowel disease, intestinal obstruction;&#xD;
&#xD;
          -  Drug abuse and medical, psychological or social conditions may interfere with&#xD;
             patients' participation in research or have an impact on the evaluation of research&#xD;
             results;&#xD;
&#xD;
          -  Known or suspected to be allergic to the study drug or to any drug given in connection&#xD;
             with this test;&#xD;
&#xD;
          -  Any unstable conditions or situations that may endanger patient safety and compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peirong Ding, Doctor</last_name>
    <phone>13543478645 Ext. +86</phone>
    <email>dingpr@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>651 Dongfeng Road East</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peirong Ding, Doctor</last_name>
      <phone>13543478645</phone>
      <phone_ext>+86</phone_ext>
      <email>dingpr@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wu Jiang, Doctor</last_name>
      <phone>15989120166</phone>
      <phone_ext>+86</phone_ext>
      <email>jiangwu@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Pei-Rong Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

